SRT3

230.1

+0.04%↑

GXI

53.75

-0.28%↓

ICAD

21.2

+0.57%↑

SRT3

230.1

+0.04%↑

GXI

53.75

-0.28%↓

ICAD

21.2

+0.57%↑

SRT3

230.1

+0.04%↑

GXI

53.75

-0.28%↓

ICAD

21.2

+0.57%↑

SRT3

230.1

+0.04%↑

GXI

53.75

-0.28%↓

ICAD

21.2

+0.57%↑

SRT3

230.1

+0.04%↑

GXI

53.75

-0.28%↓

ICAD

21.2

+0.57%↑

Search

BioMerieux

Open

SectorHealthcare

113.8 0.35

Overview

Share price change

24h

Current

Min

113

Max

114.2

Key metrics

By Trading Economics

Income

215M

Sales

785M

P/E

Sector Avg

31.236

57.333

Dividend yield

0.79

Profit margin

11.32

Employees

14,147

EBITDA

161M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+17.33% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.79%

2.63%

Market Stats

By TradingEconomics

Market Cap

-117M

13B

Previous open

113.45

Previous close

113.8

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

BioMerieux Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 kwi 2025, 08:49 UTC

Major Market Movers

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Peer Comparison

Price change

BioMerieux Forecast

Price Target

By TipRanks

17.33% upside

12 Months Forecast

Average 133.17 EUR  17.33%

High 140 EUR

Low 127 EUR

Based on 6 Wall Street analysts offering 12 month price targets forBioMerieux - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

109.6 / 118.9Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.